(Q36306259)

13 August 2017

1 reference

title

EGFR inhibitors: what have we learned from the treatment of lung cancer? (English)

1 reference

13 August 2017

Giuseppe Giaccone

1

1 reference

PubMed ID

16270096

13 August 2017

Jose Antonio Rodriguez

series ordinal

2

1 reference

13 August 2017

1 November 2005

1 reference

Nature Clinical Practice Oncology

13 August 2017

1 reference

13 August 2017

2

1 reference

13 August 2017

554-561

1 reference

13 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc0341

13 August 2017

0 references

cites work

Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Angiogenesis and lung cancer: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

EGFR mutation and response of lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Responsiveness to cetuximab without mutations in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0341

7 January 2021

Identifiers

DOI

10.1038/NCPONC0341

1 reference

PubMed ID

16270096

Dimensions Publication ID

13 August 2017

0 references

1 reference

PubMed ID

16270096